There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avidity Biosciences (RNA – Research Report), Xeris Pharmaceuticals (XERS – Research Report) and Immunovant (IMVT – Research Report) with bullish sentiments.
Avidity Biosciences (RNA)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Avidity Biosciences on November 9 and set a price target of $18.00. The company’s shares closed last Monday at $5.73, close to its 52-week low of $4.83.
According to TipRanks.com, Schwartz has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Avidity Biosciences is a Strong Buy with an average price target of $30.33, implying a 458.6% upside from current levels. In a report issued on November 9, TD Cowen also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Xeris Pharmaceuticals (XERS)
In a report issued on November 9, Roanna Ruiz from Leerink Partners maintained a Buy rating on Xeris Pharmaceuticals, with a price target of $5.00. The company’s shares closed last Monday at $1.62.
According to TipRanks.com, Ruiz is ranked 0 out of 5 stars with an average return of
Xeris Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $5.50, a 229.3% upside from current levels. In a report issued on November 10, Piper Sandler also reiterated a Buy rating on the stock with a $4.00 price target.
Immunovant (IMVT)
Leerink Partners analyst Thomas Smith maintained a Buy rating on Immunovant on November 9 and set a price target of $47.00. The company’s shares closed last Monday at $32.80.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
Currently, the analyst consensus on Immunovant is a Strong Buy with an average price target of $44.85, representing a 38.6% upside. In a report issued on October 31, Piper Sandler also maintained a Buy rating on the stock with a $57.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RNA:
- Avidity Biosciences reports Q3 EPS (71c), consensus (77c)
- Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights
- Avidity Biosciences announces AOC 1001 data from MARINA trial, MARINA-OLE study
- Biotech Alert: Searches spiking for these stocks today
- Down More Than 50%: Analysts Say Buy These 2 Beaten-Down Stocks Before They Rebound
